Atalanta Therapeutics has bagged $97 million, money the biotech plans to use to launch clinical trials for its small ...

The company has already kicked off an open-label Phase I trial of ABX1100 in Canada following positive results from a study of healthy volunteers.

Instead, the startup’s drugs employ what she described as a divalent structure in which two small-interfering RNA (siRNA) duplexes are joined by a linker. This structure enable the therapy get ...

CAMBRIDGE, Mass. - Wave Life Sciences Ltd . (NASDAQ:WVE), a clinical-stage biotechnology company with a market capitalization of $1.87 billion, has announced the commencement of its Phase 1 INLIGHT ...

The company, co-founded by Nobel Laureate Craig Mello, aims to push molecules for Huntington’s and a form of epilepsy into ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

Atalanta’s unique platform of divalent small interfering RNA (di-siRNA) enables durable, selective gene silencing throughout the brain and spinal cord. Atalanta is advancing a wholly owned ...

The oversubscribed Series B will boost the clinical development of two RNAi therapies for epilepsy and Huntington’s disease ...

Wave Life Sciences (WVE) announced clinical trial application, CTA, approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in ...

Title: Efficacy and Safety of ETX-148 in Murine Models of Haemophilia A and B Format: Oral Presentation Presentation Number: OR10 Date: 7 th February 2025 Session: SLAM e-therapeutics plc ("ETX") ...